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Scleroderma is clinically heterogeneous and a variety of plausible mechanisms of disease have been hypothesized. Recent years have
witnessed a significant improvement in overall survival although all of the gains in management have been therapies for specific organ
involvement, e.g. renal crisis and pulmonary arterial hypertension. Future studies will rely on improved clinical science, which involves
structured validation of proposed measures of outcome; development of a combined response index; and further refinement of specific
subsets of disease expression. Immunoablation with stem cell reconstitution is an example of aggressive therapy chosen as appropriate for a
particularly severe disease subset and in whom the pilot data are encouraging. Good science and clinical ethics force continued consideration
of equipoise between risk and benefit.
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Systemic sclerosis (SSc, scleroderma) remains without a clearly
defined pathogenesis and thus without an effective overarching
approach to therapy. Increasingly sophisticated scientific studies
have defined several candidate approaches of great promise
including specific molecular targets for anti-fibrotic therapy as
well as new approaches to modification of both vascular and
immunological features of disease. Many of these concepts are
addressed in this monograph. Recent advances suggest that SSc is
in fact a family of closely related illnesses wherein clinical and
serological phenotypes and specific genotype are closely inter-
related. The search for a unifying mechanism for all forms of the
syndrome, while elusive, seems within reach.
To the clinical student of scleroderma, the basic question
remains: if there were a truly effective drug for scleroderma,
how might we recognize that it worked and what standards of
response would be considered meaningful and cost effective? Is it
indeed possible that we have effective therapies in hand, yet our
methods of assessing the same have led to underestimations of
their effects?
The cluster of clinical entities incorporated under the label of
SSc is of intimidating heterogeneity. There are clear differences in
the extent and severity of skin involvement between individuals
with dcSSc vs lcSSc. This would apply if skin were considered as
the primary disease outcome under study, or if skin served merely
as a clinical surrogate for risk of accrual of visceral involvement.
Imagine a therapy that reversed skin whilst having no effect on
lung or an effective agent for interstitial lung disease that had no
discernable effect on skin. Just what sort of therapeutic response
do we expect?
Scleroderma therapeutics is advancing. Survival from sclero-
derma is improving through development of specific organ-based
strategies such as angiotensin-converting enzyme inhibitors for
scleroderma renal crisis and perhaps from modern therapies for
pulmonary vascular complications [1]. Two recent prospective
randomized controlled trials suggested that either oral or intra-
venous cyclophosphamide may slow loss of pulmonary function in
patients with scleroderma interstitial lung disease [2, 3]. These
studies illustrate a new era of sophistication in scleroderma clinical
research and in many ways raise more questions than answers.
The treatment effects for forced vital capacity (FVC) and for skin
involvement were within the laboratory range of intra-patient
variability for both measures, although secondary measures
also supported the modest efficacy of the drug. A ‘minimally
important difference’ of change in FVC, i.e. a change that
paralleled improvement in some other outcome such as survival
or quality of life has not been defined. The beneficial effect of
cyclophosphamide was not durable beyond about 6 months after
stopping cyclophosphamide, with most differences between drug
and placebo essentially absent at 24 months of follow-up [4]. In
balancing risk vs benefit, our increasing ability to define cohorts
enriched for risk of lung progression suggests that results of future
lung studies might be more easily understood. At present,
cyclophosphamide must be pronounced as effective and to be
judged as true evidence-based medicine for our clinical practices.
The issue remains the inability to state this as generalized for all
patients.
Immunoabalation with stem cell reconstitution (‘stem cell
transplant’) offers another glimpse at the future. This therapy
has a moderately high treatment-related morbidity and even
mortality, yet the magnitude of response from pilot study is
singularly impressive. Major improvements in skin and disability
and associated stabilization of visceral disease have been reported
in up to 4 yrs of follow-up [5]. Controlled follow-up trials are in
progress in both the European Union and North America.
Harmonization of inclusion and exclusion criteria as well as in
consideration of the equipoise of disease severity vs treatment-
related morbidity has been the hallmark of this endeavour. Is it
possible that treatment breakthrough in scleroderma will be a
‘trickle down’ phenomenon wherein therapy for our sickest
patients comes first followed by extrapolation to less severely
afflicted patient groups?
Much of this symposium focused on the critical science of
outcome measures. If we know what a new therapy should look
like, should not we also have confidence in our ability to measure
its effects? Collaborative exercises have led to a potential
combined response index that is currently being validated. When
multiple domains of disease are studied simultaneously, sensitivity
to change and our ability to interpret small levels of change will be
more robust [6].
New trials are actually easy to predict. We will increasingly
employ agents of highly specific effects and with strong scientific
rationale. Studies will employ consensus definitions of homo-
geneous subsets and will require multicentre collaboration for
successful and timely recruitment. Standardization of outcomes
will permit cross-study comparisons and will enhance the reservoir
of true evidence-based medicine. Regulatory agencies will benefit
from the breadth and depth of disease-specific information. Our
patients deserve nothing less than the highest standards of
efficient, ethical and rational research.
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Rheumatology key messages
 Scleroderma is pathobiologically complex and clinically
heterogeneous.
 In the absence of a disease-specific overarching mechanism,
plausible therapeutic targets are numerous.
 Development of a Combined Response Index for Systemic
Sclerosis (CRISS) may offer broad applicability as well as
enhanced sensitivity to change.
 Homogeneous subsets with common problems may be studied
although refinement of measures of outcome is needed.
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